Trump Announces Regeneron Pricing Deal as FDA Clears Hearing Gene Therapy
Deal ties Regeneron to most-favored-nation pricing on Medicaid; FDA approved Otarmeni and Regeneron will provide it free to eligible U.S. patients.
PBS NewsHourWATCH: Trump unveils deal with Regeneron to lower its drug prices for Medicaid
Epoch TimesRegeneron Strikes Drug Pricing Deal With Trump, Will Offer New Hearing-Loss Therapy for Free
NBC NewsFDA approves first gene therapy for genetic hearing loss
CNBCRegeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Overview
President Donald Trump announced a deal with Regeneron to lower U.S. drug prices under his most-favored-nation initiative, the White House said.
The Food and Drug Administration approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss, and Regeneron said it will provide the therapy at no cost to eligible U.S. patients.
Medical researchers called the approval life-changing, while Democrats in Congress have scrutinized the FDA’s Commissioner’s National Priority Voucher program, saying vouchers have gone to companies that agreed to White House pricing concessions.
Regeneron is the final company of 17 the administration approached, and those companies account for roughly 80% of the drug market; Regeneron committed nearly $27 billion in U.S. research, development and manufacturing, the White House said.
The White House has not released full deal terms, and related initiatives have faced setbacks, including an earlier Medicare delay that stalled implementation of a program to cover GLP-1 drugs, officials said.
Analysis
Center-leaning sources frame the story as both an administration win and a medical breakthrough by favoring upbeat language (e.g., "significant breakthrough," "rake in"), foregrounding Trump’s pricing deals and tariff exemptions, and quoting CMS and analysts while omitting critical voices. CMS deputy administrator’s remarks and analyst estimates are source content, not editorial framing.